Article title: Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
Author: Howard A Burris III
Journal: Expert Opinion on Biological Therapy
Bibliometrics: Volume 11, Issue 6, pages 807-819
DOI: https://doi.org/10.1517/14712598.2011.580273
Since the publication of this article, Howard A Burris III has updated his declarations.
This has now been updated in the online version of the article. The correct declaration details for H.A Burris III now read:
“Dr. Burris reports grants to his institution, Sarah Cannon Research Institute, from Novartis during the conduct of the study; grants to his institution for studies on which he served as Principal Investigator outside of the submitted work from the following companies: Alnylam Pharmaceuticals, AstraZeneca, BioMed Valley Discoveries, Inc., Eli Lilly, grants Genentech, Gloucester Pharmaceuticals, Exelixis, KuDOS Pharmaceuticals, MedImmune, Millennium Pharmaceuticals, Novartis, Niiki, Sanofi, Onyx, Otsuka, Serenex, and Threshold Pharmaceuticals; payments to his institution for consulting services performed by him from the following companies: Bristol Myers Squibb, Genentech, Novartis, Johnson & Johnson, Valent Technologies and MedImmune. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.”